Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Male
Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
Male
Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate
Trial Information
Inclusion Criteria:
- Histologically or cytologically confirmed prostate cancer.
- Prior chemotherapy regimen for prostate cancer
Exclusion Criteria:
- History of other malignancy in the last 5 years
- Major surgery within the past 21 days
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
D. Buell, MD
Investigator Role:
Study Director
Investigator Affiliation:
Astellas Pharma US, Inc.
Authority:
United States: Food and Drug Administration
Study ID:
155-CL-007
NCT ID:
NCT00257478
Start Date:
Completion Date:
March 2007
Related Keywords:
- Prostate Cancer
- Cancer of Prostate
- Prostatic Cancer
- Cancer of the Prostate
- Treatment Efficacy
- Treatment Effectiveness
- Disease Management
- Treatment
- Safety
- Prostatic Neoplasms
Name | Location |
|---|---|
| Phoenix, Arizona 85012 | |
| Fountain Valley, California 92708 | |
| Albany, New York 12208 | |
| Philadelphia, Pennsylvania 19104 | |
| Austin, Texas 78705 | |
| Coeur D'alene, Idaho 83814 |
